Post-earnings recap
Reported
Mon, Feb 23, 2026
EPS actual
$-0.06
EPS est.
$-0.08
EPS surprise
+25.00%
1-day move
+12.99%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
ImmunityBio's earnings report showed a positive surprise in EPS, which contributed to a strong stock reaction, rising nearly 13%. The company did not provide revenue figures or future guidance, leaving some uncertainty for investors. However, the management's optimistic tone may indicate confidence in their ongoing projects and future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.06 | N/A | +25.00% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting ongoing efforts in their development pipeline. They emphasized their commitment to strategic growth.
We are pleased with our progress and the positive EPS surprise.
Our focus remains on advancing our pipeline and strategic initiatives.